We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity
Read MoreHide Full Article
Alcon (ALC - Free Report) unveiled the final data from its Vivity Registry study, marking a significant milestone in the company's progress within its Surgical franchise. This study tracked real-world patient experiences following cataract surgery with AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lenses.
More on the Vivity Study Outcome
One of the major findings from the Vivity Registry study is the consistent clinical performance of AcrySof IQ Vivity, favorable for both surgeons and patients. Over 900 cataract patients participated in the study, reporting high levels of satisfaction and reduced dependence on glasses.
The study data also highlights the lens' versatility in treating a wide range of patients.
Advanced Treatment Options
The evidence suggested that AcrySof IQ Vivity can successfully address a broad spectrum of patient needs. This versatility opens up new avenues for surgeons, offering additional treatment options for patients with common comorbidities such as glaucoma, dry eye, and retinopathy/maculopathy.
Given the increased need for vision care as people age, the significance of this study result is huge. According to a Global Alcon Survey, vision is the second most important quality of aging, and cataract patients report a significant improvement in their quality of life post-surgery. Many patients are eager to reduce their dependence on glasses and AcrySof IQ Vivity provides a compelling solution.
AcrySof IQ Vivity’s extended range of vision from distance to near without increased visual disturbances addresses patients' demands and expectations for performance, quality of life and spectacle independence.
Image Source: Zacks Investment Research
Huge Market Prospects
According to a Mordor Intelligence report, the global cataract surgery devices market is poised for steady growth, projected to achieve a CAGR of 4.2% from 2022 to 2027.
Key drivers of market growth include the rising prevalence of cataracts and the increasing global geriatric population. Cataract-related visual impairment and disability-adjusted life years rates have both shown significant increases, indicating a growing demand for cataract surgery devices for treatment.
Price Performance
In the past year, ALC shares have gained 17.8% against the industry’s 6.8% decline.
Haemonetics’ stock has gained 12.5% in the past year. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 in 2023 and $3.96 to $4.07 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have soared 132.9% in the past year against the industry’s decline of 5.3%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s 2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have gained 14.4% in the past year against the industry’s decline of 5.1%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 28%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity
Alcon (ALC - Free Report) unveiled the final data from its Vivity Registry study, marking a significant milestone in the company's progress within its Surgical franchise. This study tracked real-world patient experiences following cataract surgery with AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lenses.
More on the Vivity Study Outcome
One of the major findings from the Vivity Registry study is the consistent clinical performance of AcrySof IQ Vivity, favorable for both surgeons and patients. Over 900 cataract patients participated in the study, reporting high levels of satisfaction and reduced dependence on glasses.
The study data also highlights the lens' versatility in treating a wide range of patients.
Advanced Treatment Options
The evidence suggested that AcrySof IQ Vivity can successfully address a broad spectrum of patient needs. This versatility opens up new avenues for surgeons, offering additional treatment options for patients with common comorbidities such as glaucoma, dry eye, and retinopathy/maculopathy.
Given the increased need for vision care as people age, the significance of this study result is huge. According to a Global Alcon Survey, vision is the second most important quality of aging, and cataract patients report a significant improvement in their quality of life post-surgery. Many patients are eager to reduce their dependence on glasses and AcrySof IQ Vivity provides a compelling solution.
AcrySof IQ Vivity’s extended range of vision from distance to near without increased visual disturbances addresses patients' demands and expectations for performance, quality of life and spectacle independence.
Image Source: Zacks Investment Research
Huge Market Prospects
According to a Mordor Intelligence report, the global cataract surgery devices market is poised for steady growth, projected to achieve a CAGR of 4.2% from 2022 to 2027.
Key drivers of market growth include the rising prevalence of cataracts and the increasing global geriatric population. Cataract-related visual impairment and disability-adjusted life years rates have both shown significant increases, indicating a growing demand for cataract surgery devices for treatment.
Price Performance
In the past year, ALC shares have gained 17.8% against the industry’s 6.8% decline.
Zacks Rank and Other Key Picks
Alcon currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Quanterix (QTRX - Free Report) and SiBone (SIBN - Free Report) . Each of these companies presently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics’ stock has gained 12.5% in the past year. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 in 2023 and $3.96 to $4.07 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have soared 132.9% in the past year against the industry’s decline of 5.3%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s 2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have gained 14.4% in the past year against the industry’s decline of 5.1%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 28%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.